Galen Growth Asia, the leading exclusive HealthTech research, analytics and advisory firm in Asia Pac (Asia) serving Fortune 500 companies and global investors, which has been tracking funding in Asia for the past 5+ years, has announced that the 2019 First Half Asia Pac HealthTech total funding closed at US$2.5B, across 140 deals, building on the back of a record-breaking 2018.

During the discussion, Galen Growth Asia shared 2019 Half Year Asia Healthtech Landscape report, the bi-annual go-to-reference for key trends and insights for investors, enterprises and start-ups. Early stage ventures deal activity shrinks yet further, whereas total Series B and C deal value continues to grow, grabbing 69% of total funding, raising questions regarding the sustainability of the deal flow of Growth stage investors.

Some of the key themes of this first half include:

• China slows with dollars to VC-backed ventures shrinking 49% in H1 2019 over the same period in 2018. Is the US-China geopolitical spat biting?
• India, where funding experienced a significant dip in value and volume in Q1 2019, regains speed to reach a massive US$383M.
• SE Asia (which includes Singapore, Indonesia, Malaysia, Myanmar, Vietnam, Thailand, Philippines, and other SEA) doubles and is seemingly a net winner of the trade war.

Galen Growth Asia, a Singapore company, is the leading research, analytics and advisory firm in Asia Pac serving Fortune 500 companies and global investors, exclusively HealthTech focused. Founded in late 2015 by Singapore based HealthTech innovators, Galen Growth Asia (GGA), is at the epicentre of HealthTech innovation, aka digital health, in Asia Pac currently a $75+B start-up ecosystem. GGA has built a portfolio of solutions which enables it to be the catalyst of direct collaboration between enterprises, start-ups and investors to prototype, evaluate and implement HealthTech solutions to solve healthcare system pain points and create significant financial and social value in the region.  GGA partner with enterprise, investors and startups to accelerate and deepen their understanding of this exciting ecosystem and by offering client specific analytics and advisory solutions to help them find the right options and scale their innovation plans.

Galan Growth Asia’s most comprehensive report to date is powered by HealthTech Alpha, a Galen Growth Asia (GGA) solution. HealthTech Alpha is the most advanced digital health analytics platform with best-in-class user workflow built to fast track decision making and actively monitor portfolios.

GGA provides a unique suite of solutions to enable innovation leaders to fast track the execution of their digital health strategies including curated deal flow, leadership briefings and access to the most advanced analytics platform amongst others.

Julien De Salaberry, CEO & Founder, Growth Asia explained that the “Industry and investor sentiment for HealthTech in Asia Pac continues to be very favourable. Over 90% of investors and enterprise business leaders recently surveyed confirmed that HealthTech remains a high priority for them. The Asia HealthTech Open Innovation Council membership facilitates leaders to be connected with HealthTech startups in Asia and accelerate their digital health innovation journey”.